 |
|
Absorption and Metabolism of Levodopa
William B. Abrams, MD;
Claude B. Coutinho, PhD;
Arthur S. Leon, MD;
Herbert E. Spiegel, PhD
JAMA. 1971;218(13):1912-1914.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Although levodopa is a natural body substance, it is also a new drug, and as such, information is needed on the extent and rate of absorption, the distribution in the body, and the mechanisms and rate of elimination. Furthermore, the desired actions in the brain and the central and peripheral side effects appear to be due to one or more biotransformation products rather than to levodopa itself. The current hypothesis of the mechanism of action of levodopa holds that parkinsonism is due to a deficiency of the dopaminergic neurones in the substantia nigra which terminate in the corpus striatum.1 Dopamine itself cannot be used in treatment because of its inability to cross the blood-brain barrier. However, levodopa, an amino acid, enters the brain and is readily decarboxylated to dopamine. Thus, the metabolism of levodopa is of great clinical significance.
In our laboratories, absorption and metabolism studies have been conducted
. . . [Full Text PDF of this Article]
Author Affiliations
From the Department of Clinical Pharmacology, Hoffmann-La-Roche, Inc., Nutley, NJ. Dr. Abrams is now with Ayerst Laboratories, New York.
Footnotes
Read before the Section on Clinical Pharmacology and Therapeutics at the 119th annual convention of the American Medical Association, Chicago, June 22, 1970.
Reprint requests to Hoffmann-LaRoche, Inc., Nutley, NJ 07110 (Dr. Leon).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
